DDInter410 DDInter1676
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic ser
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Clomipramine {u} (Compound) resembles {v} (Compound) Adinazolam
Clomipramine {u} (Compound) resembles {v} (Compound) Thioridazine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Clomipramine {u} (Compound) binds {v} (Gene) CYP1A2
Clomipramine {u} (Compound) upregulates {v} (Gene) TGFBR2
Clomipramine {u} (Compound) palliates {v} (Disease) panic disorder
Clomipramine {u} (Compound) causes {v} (Side Effect) Uterine haemorrhage
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ammonium chloride
Clomipramine (Compound) resembles Adinazolam (Compound)
Clomipramine (Compound) resembles Thioridazine (Compound)
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Clomipramine (Compound) binds CYP1A2 (Gene)
Clomipramine (Compound) upregulates TGFBR2 (Gene)
Clomipramine (Compound) palliates panic disorder (Disease)
Clomipramine (Compound) causes Uterine haemorrhage (Side Effect)
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride